ClinicalTrials.gg
CompletedNCT03099187Updated Jan 13, 2021Results posted

A Study of Pirfenidone in Patients With Unclassifiable Progressive Fibrosing Interstitial Lung Disease

A Phase 2 interventional study of Pirfenidone and Placebo in Lung Diseases, Interstitial, sponsored by Hoffmann-La Roche. Completed at 66 sites in 14 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2021-01-13.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
253
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 13 studies testing pirfenidone in Lung Diseases, Interstitial — 1 open to participants now, 2 under way, none of them phase 3. pirfenidone · Lung Diseases, Interstitial.

Enrollment
Largest of 13
253 · median 120
Started
2017
with 3 others
Phase 2
8 of 13
none open now
Registered
5th of 13
by date
Lead sponsor
1 of 13
Hoffmann-La Roche

Among the 13 studies testing pirfenidone in Lung Diseases, Interstitial, this one has the largest enrollment, is one of 4 that started in 2017, is one of 8 in phase 2, and was the 5th registered.

Lung Diseases, Interstitial

682 studies on the registry are indexed under Lung Diseases, Interstitial; 245 are open to participants now.

Browse Lung Diseases, Interstitial studies →

Open to participants now

1 of the 13 studies testing pirfenidone in Lung Diseases, Interstitial is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About pirfenidone

pirfenidone: first FDA approval 2014 (ESBRIET), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 172 Lung Diseases, Interstitial studies recruiting now, 108 (63%) set no upper age limit and 25 (15%) stop at 75 or younger; 13 take children under 18; 21 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing pirfenidone in Lung Diseases, Interstitial, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of pirfenidone in participants with fibrosing interstitial lung disease (ILD) who cannot be classified with moderate or high confidence into any other category of fibrosing ILD by multidisciplinary team (MDT) review ("unclassifiable" ILD).

Read the detailed description

Study participants will be randomised to receive 801 mg pirfenidone or placebo three times daily for 24 weeks. The efficacy of pirfenidone versus placebo will be assessed by daily measurement of forced vital capacity using a handheld spirometer over the treatment period. Additionally, the study will assess the efficacy and safety of pirfenidone with and without concomitant mycophenolate mofetil treatment and in study participants with or without interstitial pneumonia with autoimmune features (IPAF). All study participants who attend the follow-up visit at Week 28 will be offered the opportunity to receive open-label pirfenidone within the trial protocol. In order to maintain blinding of the controlled period of the study, all study participants will discontinue treatment by Week 24 and return for a follow-up visit 4 weeks later. Study participants eligible to participate in the single-arm 12-month extension will be initiated on open-label pirfenidone during this visit (re-starting the dose titration from one capsule three times daily [TID]). During the long-term extension period, study participants will be monitored for safety, initially at monthly visits during the first 6 months and thereafter approximately every 3 months. A final follow-up visit will take place 4 weeks after the last dose of pirfenidone is taken.

03

Conditions studied

  • Lung Diseases, Interstitial
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age >= 18-85 years
  • Confirmed fibrosing ILD which, following multidisciplinary team review, cannot be classified with either high or moderate confidence as a specific idiopathic interstitial pneumonia or other defined ILD
  • Progressive disease as considered by the investigator as participants deterioration within the last 6 months, which is defined as a rate of decline in forced vital capacity (FVC) >5% or a significant symptomatic worsening not due to cardiac, pulmonary vascular or other causes
  • Extent of fibrosis >10% on high-resolution computed tomography
  • Forced vital capacity >= 45% of predicted value
  • Diffusing capacity of the lung for carbon monoxide (DLco) >= 30% of predicted value
  • /FVC ratio >= 0.7
  • Able to do 6-minute walk distance (6MWD) >= 150 meters
  • For women of : agreement to remain abstinent or use a non-hormonal or hormonal method with a failure rate of \< 1% per year during the treatment period and for at least 90 days after the last dose of pirfenidone
  • For men, agreement to remain abstinent or use contraceptive measures, and agreement to refrain from donating sperm

Exclusion criteria

Exclusion Criteria:

  • Diagnosis with moderate or high confidence of nonspecific interstitial pneumonia and any ILD with an identifiable cause such as connective tissue disease-ILD, chronic pneumonitis, or others
  • Diagnosis of idiopathic pulmonary fibrosis independent of the confidence level
  • History of unstable angina or myocardial infarction during the previous 6 months
  • Treatment with high dose systemic , or any other than mycophenolate mofetil/acid (MMF), at any time within the 4 weeks of the screening period. Participants being treated with MMF should be on a stable dose that is expected to remain stable throughout the trial and was started at least 3 months prior to screening
  • Participants previously treated with pirfenidone or nintedanib
  • Participants treated with N-acetyl-cysteine for fibrotic lung disease, at any time within the 4 weeks of the screening period
  • Drug treatment for any type of pulmonary hypertension
  • Participation in a trial of an medicinal product within the last 4 weeks
  • Significant other organ co-morbidity including hepatic or renal impairment
  • Predicted \< 12 months or on an active transplant waiting list
  • Use of any tobacco product in the 12 weeks prior to the start of screening, or any unwillingness to abstain from their use through to the Follow-up Visit
  • Illicit drug or alcohol abuse within 12 months prior to screening
  • Planned major surgery during the trial
  • Hypersensitivity to the active substance or to any of the of pirfenidone
  • History of angioedema
  • Concomitant use of fluvoxamine
  • Clinical evidence of any active infection
  • Any history of hepatic impairment, elevation of transaminase enzymes, or liver function test results as: Total above the (ULN), or alanine aminotransferase >1.5 × ULN, and Alkaline phosphatase >2.0 × ULN
  • \< 30 milliliter (mL) per minute, calculated using the Cockcroft-Gault formula
  • Any serious medical condition, abnormality on an (ECG) at screening, or laboratory test results
  • An ECG with a heart rate interval using Fridericia's formula as >= 500 milliseconds at screening, or a family or personal history of long QT syndrome
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
253 participants (actual)

Study arms

  • Experimental
    Pirfenidone

    Participants will receive pirfenidone 267 mg capsule three times a day from Day 1 to 7 followed by 2 capsules three times a day from Day 8 to 14 then 3 capsules three times a day from Day 15 up to Week 24.

    Drug: Pirfenidone

  • Experimental
    Placebo

    Participants will receive matching placebo capsule three times a day from Day 1 to 7 followed by 2 capsules three times a day from Day 8 to 14 then 3 capsules three times a day from Day 15 up to Week 24.

    Drug: Placebo

Interventions

  • Pirfenidone 267 mg capsules three times in a day.

  • DrugPlacebo

    Matching placebo capsules three times in a day.

06

What researchers measure

Primary outcomes

  1. Rate of Decline in Forced Vital Capacity (FVC) Over the 24-week Double-blind Treatment Period

    Rate of decline in FVC was measured in mL by daily handheld spirometer. The analyses were repeated due to an additional independent review of the home spirometry data.

    Time frame: Up to Week 24

Secondary outcomes

  1. Change in Percent Predicted FVC

    FVC was measured in liter (L) by spirometry. The analyses were repeated due to additional data cleaning activities that were not conducted during the primary analysis.

    Time frame: Baseline (Day 1) to Week 24

  2. Change in FVC

    FVC was measured in liter (L) by spirometry. The analyses were repeated due to additional data cleaning activities that were not conducted during the primary analysis.

    Time frame: Baseline (Day 1) to Week 24

  3. Categorical Change in FVC of >5%

    Categorical change in FVC was measured both by daily spirometry as well as by spirometry during clinical visits. Only the site spirometry data were used as the daily spirometry data were not normally distributed. The analyses were repeated due to additional data cleaning activities that were not conducted during the primary analysis.

    Time frame: Baseline (Day 1) to Week 24

  4. Categorical Change in FVC of >10%

    Categorical change in FVC was measured both by daily spirometry as well as by spirometry during clinical visits. Only the site spirometry data were used as the daily spirometry data were not normally distributed. The analyses were repeated due to additional data cleaning activities that were not conducted during the primary analysis.

    Time frame: Baseline (Day 1) to Week 24

  5. Change in Percent Predicted Diffusing Capacity of the Lung for Carbon Monoxide (DLco)

    The DLco is a pulmonary function test that measures the capacity for the lung to carry out gas exchange between the inhaled breath and the pulmonary capillary blood vessels and the DLco %-predicted represents the DLco expressed as a percentage of the expected normal valued based on the participant's age, height, gender and ethnicity.

    Time frame: Baseline (Day 1) to Week 24

  6. Change in 6-minute Walk Distance (6MWD)

    Comparison of 6-minute walk distance before beginning and after completing study therapy.

    Time frame: Baseline (Day 1) to Week 24

  7. Change in University of California, San Diego-Shortness of Breath Questionnaire Score

    University of California, San Diego Shortness of Breath Questionnaire (SOBQ) consists of 24-item on a scale of 0 to 5 with 0=not at all and 5=maximal or unable to do because of breathlessness. The total scores were calculated by summation of the 24 items scores and transformed into 0-100, with 0= poor quality of life , and 100= excellent quality of life.

    Time frame: Baseline (Day 1) to Week 24

  8. Change in Score in Leicester Cough Questionnaire Score

    The Leicester Cough Questionnaire is a patient-reported questionnaire evaluating the impact of cough on quality of life. The questionnaire comprises 19 items. Each item assesses symptoms, or the impact of symptoms, over the last 2 weeks on a seven-point Likert scale. Scores in three domains (physical, psychological and social) were calculated as a mean for each domain (range 1 to 7). A total score (range 3 to 21) was also calculated by adding the domain scores together. Higher scores indicate better quality of life.

    Time frame: Baseline (Day 1) to Week 24

  9. Change in Cough Visual Analog Scale (VAS) Score

    Cough VAS are 100-mm linear scales on which participants indicate the severity of their cough; 0 mm represents no cough and 100 mm the worst cough ever.

    Time frame: Baseline (Day 1) to Week 24

  10. Change in Total and Sub-scores of the Saint George's Respiratory Questionnaire (SGRQ)

    The SGRQ is a 50-item questionnaire developed to measure health status (quality of life) in participants with diseases of airways obstruction. Three component scores are: Symptoms (respiratory symptoms and severity); Activity (activities that cause or are limited by breathlessness); Impacts (social functioning and psychological disturbances due to airway disease). Each component sub-scores are calculated from the summed weights for the positive responses to questions. Total score summaries the impact of disease on overall health status. Scores are expressed as a percentage of overall impairment where 100 represents worst possible health status and 0 indicates best possible health status. It is calculated by summing all positive responses in the questionnaire and expressing the result as a percentage of the total weight for the questionnaire.

    Time frame: Baseline (Day 1) to Week 24

  11. Number of Participants With Non-elective Hospitalization, Both Respiratory and All Cause

    Participants with non-elective hospitalization are reported.

    Time frame: Baseline (Day 1) to Week 24

  12. Percentage of Participants With Investigator-reported Acute Exacerbations

    Percentage of participants with acute exacerbation arereported.

    Time frame: Baseline (Day 1) to Week 24

  13. Time to First Investigator-reported Acute Exacerbations

    Time to first investigator reported acute exacerbations from start of treatment are reported.

    Time frame: Baseline (Day 1) to Week 24

  14. Progression-free Survival (PFS)

    PFS is defined as the time to the first occurrence of a \>10% absolute decline in percent predicted FVC, a \>50 m decline of 6MWD, or death.

    Time frame: Baseline (Day 1) to Week 24

  15. Progression-free Survival (PFS)

    PFS is defined as the time to the first occurrence of a \>10% relative decline in percent predicted FVC, non-elective respiratory hospitalization, or death.

    Time frame: Baseline (Day 1) to Week 24

  16. Time to Death From Any Cause

    Time to first documented death from start of treatment is reported.

    Time frame: Baseline (Day 1) to Week 24

  17. Time to Death From Respiratory Diseases

    Time to first documented death due to respiratory diseases from start of treatment will be reported.

    Time frame: Baseline (Day 1) to Week 24

  18. Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    An adverse event is any untoward medical occurrence in a subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.

    Time frame: Baseline (Day 1) to Week 28

  19. Number of Participants With Dose Reductions and Treatment Interruptions During the Double-Blind Period

    Number of participants with dose reduction and treatment interruptions are reported.

    Time frame: From administration of the first dose of study drug to Week 24

  20. Number of Participants With Dose Reductions and Treatment Interruptions During the 12-month Safety Follow-up

    Number of participants with dose reduction and treatment interruptions are reported.

    Time frame: From the Follow-up Visit at Week 28 through the follow-up period of 12 Months

  21. Number of Participants Withdrawn From Trial Treatment or Trial Discontinuations During the Double-Blind Period

    Number of participants withdrawn from trial treatment or trial discontinuations are reported.

    Time frame: Baseline (Day 1) to Week 24

  22. Number of Participants Withdrawn From Trial Treatment or Trial Discontinuations During the 12-month Safety Follow-up

    Number of participants withdrawn from trial treatment or trial discontinuations are reported.

    Time frame: From the Follow-up Visit at Week 28 through the follow-up period of 12 Months

07

Results

Posted Jan 3, 2020

Participant flow

Double-blind Treatment
Participant flow — Double-blind Treatment
MilestonePirfenidonePlaceboOpen-Label Treatment (Pirfenidone)Open-Label Treatment (Placebo)
Started12712600
Completed9411000
Not completed331600
Withdrew: Adverse event19100
Withdrew: Death1300
Withdrew: Lack of efficacy1000
Withdrew: Physician decision2100
Withdrew: Withdrawal by subject9400
Withdrew: Lung transplantation0100
Withdrew: Non-compliance with study drug0200
Withdrew: Disease progression0100
Withdrew: Randomization error0200
Withdrew: Non-compliance with protocol procedure1100
12-month Safety Follow-up
Participant flow — 12-month Safety Follow-up
MilestonePirfenidonePlaceboOpen-Label Treatment (Pirfenidone)Open-Label Treatment (Placebo)
Started0094110
Completed007584
Not completed001926
Withdrew: Adverse event00512
Withdrew: Death0079
Withdrew: Lung transplantation0021
Withdrew: Lost to follow-up0010
Withdrew: Symptomatic deterioration0011
Withdrew: Withdrawal by subject0032
Withdrew: Due to hospitalization0001

Outcome measures

PrimaryRate of Decline in Forced Vital Capacity (FVC) Over the 24-week Double-blind Treatment Period

Rate of decline in FVC was measured in mL by daily handheld spirometer. The analyses were repeated due to an additional independent review of the home spirometry data.

Time frame:
Up to Week 24
Reported as:
Mean · milliliter (mL)
Rate of Decline in Forced Vital Capacity (FVC) Over the 24-week Double-blind Treatment Period
milliliter (mL)PirfenidonePlacebo
Primary Analysis in 2019-17.9 (-311.7 to 275.9)116.6 (-451.9 to 685.2)
Final Analysis in 2020-90.3 (-157.0 to -23.7)125.6 (-458.4 to 709.6)
Statistical analysis
  • Pirfenidone vs Placebo · t-test, 2 sided · p = 0.6777 (p-value was not adjusted for multiplicity and is provided for descriptive purpose only) · Difference in group means: -134.6 · 95% CI -772.4 to 503.3
  • Pirfenidone vs Placebo · Student's t-test · p = 0.4682 (p-value was not adjusted for multiplicity and is provided for descriptive purpose only) · Difference in group means: -216.0 · 95% CI -803.6 to 371.7
SecondaryChange in Percent Predicted FVC

FVC was measured in liter (L) by spirometry. The analyses were repeated due to additional data cleaning activities that were not conducted during the primary analysis.

Time frame:
Baseline (Day 1) to Week 24
Reported as:
Mean · Percent predicted (%)
Change in Percent Predicted FVC
Percent predicted (%)PirfenidonePlacebo
Baseline (Day 1)73.95 ± 18.81573.95 ± 19.974
Week 474.04 ± 19.00974.55 ± 21.223
Week 873.98 ± 19.32473.50 ± 20.168
Week 1273.96 ± 19.49373.91 ± 20.856
Week 1674.56 ± 20.29972.65 ± 22.479
Week 2073.94 ± 21.00071.99 ± 21.673
Week 2472.95 ± 20.81973.55 ± 22.383
Statistical analysis
  • Pirfenidone vs Placebo · rank ANCOVA · p = 0.0383
  • Pirfenidone vs Placebo · rank ANCOVA · p = 0.0239
SecondaryChange in FVC

FVC was measured in liter (L) by spirometry. The analyses were repeated due to additional data cleaning activities that were not conducted during the primary analysis.

Time frame:
Baseline (Day 1) to Week 24
Reported as:
Mean · Liter (L)
Change in FVC
Liter (L)PirfenidonePlacebo
Baseline2.36 ± 0.7932.38 ± 0.747
Week 42.37 ± 0.8182.37 ± 0.786
Week 82.37 ± 0.8222.36 ± 0.816
Week 122.37 ± 0.8202.35 ± 0.773
Week 162.41 ± 0.8602.31 ± 0.782
Week 202.40 ± 0.8662.30 ± 0.796
Week 242.37 ± 0.8632.34 ± 0.773
Statistical analysis
  • Pirfenidone vs Placebo · Student's t-test · p = 0.0018 (p-value was not adjusted for multiplicity and was provided for descriptive purpose only) · Overall mean difference: 95.3 · 95% CI 35.9 to 154.6
  • Pirfenidone vs Placebo · Student's t-test · p = 0.0096 (p-value was not adjusted for multiplicity and was provided for descriptive purpose only) · Overall mean difference: 84.3 · 95% CI 20.7 to 147.8
SecondaryCategorical Change in FVC of >5%

Categorical change in FVC was measured both by daily spirometry as well as by spirometry during clinical visits. Only the site spirometry data were used as the daily spirometry data were not normally distributed. The analyses were repeated due to additional data cleaning activities that were not conducted during the primary analysis.

Time frame:
Baseline (Day 1) to Week 24
Reported as:
Number · Number of Participants
Categorical Change in FVC of >5%
Number of ParticipantsPirfenidonePlacebo
Primary Analysis in 20194774
Final Analysis in 20204773
Statistical analysis
  • Pirfenidone vs Placebo · Cochran-Mantel-Haenszel · p = 0.0006 (p-value was not adjusted for multiplicity and was provided for descriptive purpose only) · Odds ratio (or): 0.42 · 95% CI 0.25 to 0.69
  • Pirfenidone vs Placebo · Cochran-Mantel-Haenszel · p = 0.0009 (p-value was not adjusted for multiplicity and was provided for descriptive purpose only) · Odds ratio (or): 0.43 · 95% CI 0.26 to 0.71
SecondaryCategorical Change in FVC of >10%

Categorical change in FVC was measured both by daily spirometry as well as by spirometry during clinical visits. Only the site spirometry data were used as the daily spirometry data were not normally distributed. The analyses were repeated due to additional data cleaning activities that were not conducted during the primary analysis.

Time frame:
Baseline (Day 1) to Week 24
Reported as:
Number · Number of Participants
Categorical Change in FVC of >10%
Number of ParticipantsPirfenidonePlacebo
Primary Analysis in 20191834
Final Analysis in 20201833
Statistical analysis
  • Pirfenidone vs Placebo · Cochran-Mantel-Haenszel · p = 0.0114 (p-value was not adjusted for multiplicity and was provided for descriptive purpose only) · Odds ratio (or): 0.44 · 95% CI 0.23 to 0.84
  • Pirfenidone vs Placebo · Cochran-Mantel-Haenszel · p = 0.0168 (p-value was not adjusted for multiplicity and was provided for descriptive purpose only) · Odds ratio (or): 0.46 · 95% CI 0.24 to 0.88
SecondaryChange in Percent Predicted Diffusing Capacity of the Lung for Carbon Monoxide (DLco)

The DLco is a pulmonary function test that measures the capacity for the lung to carry out gas exchange between the inhaled breath and the pulmonary capillary blood vessels and the DLco %-predicted represents the DLco expressed as a percentage of the expected normal valued based on the participant's age, height, gender and ethnicity.

Time frame:
Baseline (Day 1) to Week 24
Reported as:
Mean · % predicted
Change in Percent Predicted Diffusing Capacity of the Lung for Carbon Monoxide (DLco)
% predictedPirfenidonePlacebo
Baseline (Day 1)46.19 ± 12.40349.57 ± 13.931
Change from Baseline at Week 12 (Primary Analysis in 2019)-0.52 ± 6.193-0.56 ± 8.807
Change from Baseline at Week 24 (Primary Analysis in 2019)-0.65 ± 7.113-2.47 ± 8.833
Change from Baseline at Week 12 (Final Analysis in 2020)-0.52 ± 6.193-0.89 ± 9.407
Change from Baseline at Week 24 (Final Analysis in 2020)-0.65 ± 7.113-2.48 ± 8.893
Statistical analysis
  • Pirfenidone vs Placebo · rank ANCOVA · p = 0.0874 (p-value was not adjusted for multiplicity and was provided for descriptive purpose only)
  • Pirfenidone vs Placebo · rank ANCOVA · p = 0.1191 (p-values are not adjusted for multiplicity and are provided for descriptive purpose only.)
SecondaryChange in 6-minute Walk Distance (6MWD)

Comparison of 6-minute walk distance before beginning and after completing study therapy.

Time frame:
Baseline (Day 1) to Week 24
Reported as:
Mean · meter (m)
Change in 6-minute Walk Distance (6MWD)
meter (m)PirfenidonePlacebo
Baseline391.6 ± 114.93394.0 ± 108.09
Change from Baseline at Week 12-14.8 ± 66.23-7.7 ± 57.60
Change from Baseline at Week 24-2.0 ± 68.11-26.7 ± 79.32
Statistical analysis
  • Pirfenidone vs Placebo · rank ANCOVA · p = 0.0395 (p-value was not adjusted for multiplicity and was provided for descriptive purpose only)
  • Pirfenidone vs Placebo · rank ANCOVA · p = 0.0299 (p-value was not adjusted for multiplicity and was provided for descriptive purpose only)
SecondaryChange in University of California, San Diego-Shortness of Breath Questionnaire Score

University of California, San Diego Shortness of Breath Questionnaire (SOBQ) consists of 24-item on a scale of 0 to 5 with 0=not at all and 5=maximal or unable to do because of breathlessness. The total scores were calculated by summation of the 24 items scores and transformed into 0-100, with 0= poor quality of life , and 100= excellent quality of life.

Time frame:
Baseline (Day 1) to Week 24
Reported as:
Mean · Scores on a Scale
Change in University of California, San Diego-Shortness of Breath Questionnaire Score
Scores on a ScalePirfenidonePlacebo
Baseline44.17 ± 25.20448.89 ± 23.441
Change from Baseline at Week 121.47 ± 19.7072.24 ± 18.617
Change from Baseline at Week 245.21 ± 18.7015.30 ± 22.078
Statistical analysis
  • Pirfenidone vs Placebo · rank ANCOVA · p = 0.7788 · Hodges-lehmann median difference: 0.00 · 95% CI -5.00 to 5.00Analysis of Covariance Changes from baseline to week 24 are compared between the treatment arms using a rank ANCOVA.
  • Pirfenidone vs Placebo · rank ANCOVA · p = 0.8289 (Analysis of Covariance Changes from baseline to week 24 or early discontinuation visit are compared between the treatment arms using a rank ANCOVA with change from baseline as outcome variable and standardized rank baseline value as covariate) · Hodges-lehmann median difference: 0.00 · 95% CI -5.00 to 5.00
SecondaryChange in Score in Leicester Cough Questionnaire Score

The Leicester Cough Questionnaire is a patient-reported questionnaire evaluating the impact of cough on quality of life. The questionnaire comprises 19 items. Each item assesses symptoms, or the impact of symptoms, over the last 2 weeks on a seven-point Likert scale. Scores in three domains (physical, psychological and social) were calculated as a mean for each domain (range 1 to 7). A total score (range 3 to 21) was also calculated by adding the domain scores together. Higher scores indicate better quality of life.

Time frame:
Baseline (Day 1) to Week 24
Reported as:
Mean · Scores on a Scale
Change in Score in Leicester Cough Questionnaire Score
Scores on a ScalePirfenidonePlacebo
Baseline16.13 ± 3.71115.15 ± 3.928
Change from Baseline at Week 12 (Primary Analysis in 2019)0.35 ± 2.903-0.23 ± 3.654
Change from Baseline at Week 24 (Primary Analysis in 2019)0.36 ± 2.8890.04 ± 3.702
Change from Baseline at Week 12 (Final Analysis in 2020)0.35 ± 2.903-0.23 ± 3.654
Change from Baseline at Week 24 (Final Analysis in 2020)0.35 ± 2.8840.04 ± 3.702
Statistical analysis
  • Pirfenidone vs Placebo · rank ANCOVA · p = 0.1872 (p-value was not adjusted for multiplicity and was provided for descriptive purpose only) · Hodges-lehmann median difference: 0.29 · 95% CI -0.45 to 1.04Analysis of Covariance Changes from baseline to week 24 are compared between the treatment arms using a rank ANCOVA.
  • Pirfenidone vs Placebo · rank ANCOVA · p = 0.2019 (Analysis of Covariance Changes from baseline to week 24 or early discontinuation visit are compared between the treatment arms using a rank ANCOVA with change from baseline as outcome variable and standardized rank baseline value as covariate.) · Hodges-lehmann median difference: 0.27 · 95% CI -0.48 to 1.02
SecondaryChange in Cough Visual Analog Scale (VAS) Score

Cough VAS are 100-mm linear scales on which participants indicate the severity of their cough; 0 mm represents no cough and 100 mm the worst cough ever.

Time frame:
Baseline (Day 1) to Week 24
Reported as:
Mean · millimeter (mm)
Change in Cough Visual Analog Scale (VAS) Score
millimeter (mm)PirfenidonePlacebo
Baseline35.60 ± 27.49737.18 ± 26.270
Change from Baseline at Week 12-4.33 ± 20.0173.32 ± 26.429
Change from Baseline at Week 24-2.52 ± 26.7200.78 ± 30.121
Statistical analysis
  • Pirfenidone vs Placebo · rank ANCOVA · p = 0.2995 · Hodges-lehmann median difference: -2.00 · 95% CI -10.00 to 4.00Analysis of Covariance Changes from baseline to week 24 are compared between the treatment arms using a rank ANCOVA.
  • Pirfenidone vs Placebo · rank ANCOVA · p = 0.3372 (Analysis of Covariance Changes from baseline to week 24 or early discontinuation visit are compared between the treatment arms using a rank ANCOVA with change from baseline as outcome variable and standardized rank baseline value as covariate.) · Hodges-lehmann median difference: -2.00 · 95% CI -10.00 to 4.00
SecondaryChange in Total and Sub-scores of the Saint George's Respiratory Questionnaire (SGRQ)

The SGRQ is a 50-item questionnaire developed to measure health status (quality of life) in participants with diseases of airways obstruction. Three component scores are: Symptoms (respiratory symptoms and severity); Activity (activities that cause or are limited by breathlessness); Impacts (social functioning and psychological disturbances due to airway disease). Each component sub-scores are calculated from the summed weights for the positive responses to questions. Total score summaries the impact of disease on overall health status. Scores are expressed as a percentage of overall impairment where 100 represents worst possible health status and 0 indicates best possible health status. It is calculated by summing all positive responses in the questionnaire and expressing the result as a percentage of the total weight for the questionnaire.

Time frame:
Baseline (Day 1) to Week 24
Reported as:
Mean · Scores of a Scale
Change in Total and Sub-scores of the Saint George's Respiratory Questionnaire (SGRQ)
Scores of a ScalePirfenidonePlacebo
Symptoms sub-score - Baseline49.28 ± 21.68753.10 ± 21.450
Change from Baseline in Symptoms sub-score at Week 12-2.60 ± 19.1730.86 ± 16.212
Change from Baseline in Symptoms sub-score at Week 24-1.69 ± 19.186-0.66 ± 15.407
Activities sub-score - Baseline63.93 ± 20.38866.96 ± 18.615
Change from Baseline in Activities sub-score at Week 121.17 ± 13.3761.13 ± 13.704
Change from Baseline in Activities sub-score at Week 241.25 ± 14.6292.22 ± 13.110
Impacts sub-score - Baseline37.12 ± 20.48441.47 ± 20.520
Change from Baseline in Impacts sub-score at Week 120.29 ± 16.8260.33 ± 13.888
Change from Baseline in Impacts sub-score at Week 24-0.18 ± 13.8841.07 ± 17.539
Total score - Baseline47.37 ± 18.46551.46 ± 17.699
Change from Baseline in Total score at Week 12-0.17 ± 13.6330.53 ± 11.724
Change from Baseline in Total score at Week 240.05 ± 12.5490.85 ± 13.383
Statistical analysis
  • Pirfenidone vs Placebo · rank ANCOVA · p = 0.1630 · Hodges-lehmann median difference: -1.86 · 95% CI -5.06 to 1.38Analysis of Covariance Changes from baseline to week 24 are compared between the treatment arms using a rank ANCOVA.
  • Pirfenidone vs Placebo · rank ANCOVA · p = 0.1851 (Analysis of Covariance Changes from baseline to week 24 or early discontinuation visit are compared between the treatment arms using a rank ANCOVA with change from baseline as outcome variable and standardized rank baseline value as covariate.) · Hodges-lehmann median difference: -1.74 · 95% CI -5.00 to 1.55
SecondaryNumber of Participants With Non-elective Hospitalization, Both Respiratory and All Cause

Participants with non-elective hospitalization are reported.

Time frame:
Baseline (Day 1) to Week 24
Reported as:
Number · Number of Participants
Number of Participants With Non-elective Hospitalization, Both Respiratory and All Cause
Number of ParticipantsPirfenidonePlacebo
All-cause hospitalization1613
Respiratory-related hospitalization55
Statistical analysis
  • Pirfenidone vs Placebo · Log Rank · p = 0.5922 · Hazard ratio (hr): 1.22 · 95% CI 0.59 to 2.49Hazard ratios and corresponding 95% CI are calculated by applying Cox-proportional hazard models.
  • Pirfenidone vs Placebo · Log Rank · p = 0.8057 · Hazard ratio (hr): 0.86 · 95% CI 0.26 to 2.83Hazard ratios and corresponding 95% CI are calculated by applying Cox-proportional hazard models.
  • Pirfenidone vs Placebo · Log Rank · p = 0.4613 · Hazard ratio (hr): 1.31 · 95% CI 0.63 to 2.73Hazard ratios and corresponding 95% CI are calculated by applying Cox-proportional hazard models
  • Pirfenidone vs Placebo · Log Rank · p = 0.9523 · Hazard ratio (hr): 1.04 · 95% CI 0.30 to 3.59Hazard ratios and corresponding 95% CI are calculated by applying Cox-proportional hazard models.
SecondaryPercentage of Participants With Investigator-reported Acute Exacerbations

Percentage of participants with acute exacerbation arereported.

Time frame:
Baseline (Day 1) to Week 24
Reported as:
Number · Percentage of Participants
Percentage of Participants With Investigator-reported Acute Exacerbations
Percentage of ParticipantsPirfenidonePlacebo
Percentage of Participants With Investigator-reported Acute Exacerbations3.95.6
SecondaryTime to First Investigator-reported Acute Exacerbations

Time to first investigator reported acute exacerbations from start of treatment are reported.

Time frame:
Baseline (Day 1) to Week 24
Reported as:
Median · Weeks
Time to First Investigator-reported Acute Exacerbations
WeeksPirfenidonePlacebo
Time to First Investigator-reported Acute ExacerbationsNA (NA to NA)NA (NA to NA)
Statistical analysis
  • Pirfenidone vs Placebo · Log Rank · p = 0.7871 · Hazard ratio (hr): 0.85 · 95% CI 0.26 to 2.78
SecondaryProgression-free Survival (PFS)

PFS is defined as the time to the first occurrence of a \>10% absolute decline in percent predicted FVC, a \>50 m decline of 6MWD, or death.

Time frame:
Baseline (Day 1) to Week 24
Reported as:
Median · Week
Progression-free Survival (PFS)
WeekPirfenidonePlacebo
Progression-free Survival (PFS)25.14 (24.14 to NA)24.71 (24.14 to NA)
Statistical analysis
  • Pirfenidone vs Placebo · Log Rank · p = 0.3660 · Cox proportional hazard: 0.84 · 95% CI 0.56 to 1.24Log-rank tests based on the time to the first event are to compare the two treatment arms.
  • Pirfenidone vs Placebo · Log Rank · p = 0.4173 · Cox proportional hazard: 0.85 · 95% CI 0.57 to 1.26Log-rank tests based on the time to the first event are to compare the two treatment arms.
SecondaryProgression-free Survival (PFS)

PFS is defined as the time to the first occurrence of a \>10% relative decline in percent predicted FVC, non-elective respiratory hospitalization, or death.

Time frame:
Baseline (Day 1) to Week 24
Reported as:
Median · Week
Progression-free Survival (PFS)
WeekPirfenidonePlacebo
Progression-free Survival (PFS)NA (24.86 to NA)NA (24.14 to NA)
Statistical analysis
  • Pirfenidone vs Placebo · Log Rank · p = 0.2726 · Cox proportional hazard: 0.79 · 95% CI 0.52 to 1.20Log-rank tests based on the time to the first event are to compare the two treatment arms.
  • Pirfenidone vs Placebo · Log Rank · p = 0.3386 · Cox proportional hazard: 0.82 · 95% CI 0.54 to 1.24Log-rank tests based on the time to the first event are to compare the two treatment arms.
SecondaryTime to Death From Any Cause

Time to first documented death from start of treatment is reported.

Time frame:
Baseline (Day 1) to Week 24
Reported as:
Median · Week
Time to Death From Any Cause
WeekPirfenidonePlacebo
Time to Death From Any CauseNA (NA to NA)NA (NA to NA)
Statistical analysis
  • Pirfenidone vs Placebo · Log Rank · p = 0.9969 · Cox proportional hazard: 1.01 · 95% CI 0.06 to 16.08Log-rank tests based on the time to the first event are to compare the two treatment arms.
SecondaryTime to Death From Respiratory Diseases

Time to first documented death due to respiratory diseases from start of treatment will be reported.

Time frame:
Baseline (Day 1) to Week 24
Reported as:
Median · Week
Time to Death From Respiratory Diseases
WeekPirfenidonePlacebo
Time to Death From Respiratory DiseasesNA (NA to NA)NA (NA to NA)
Statistical analysis
  • Pirfenidone vs Placebo · Log Rank · p = 0.3231Log-rank tests based on the time to the first event are to compare the two treatment arms.
SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs)

An adverse event is any untoward medical occurrence in a subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.

Time frame:
Baseline (Day 1) to Week 28
Reported as:
Number · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
ParticipantsPirfenidonePlacebo
Number of Participants With Treatment-emergent Adverse Events (TEAEs)120101
SecondaryNumber of Participants With Dose Reductions and Treatment Interruptions During the Double-Blind Period

Number of participants with dose reduction and treatment interruptions are reported.

Time frame:
From administration of the first dose of study drug to Week 24
Reported as:
Number · Number of Participants
Number of Participants With Dose Reductions and Treatment Interruptions During the Double-Blind Period
Number of ParticipantsPirfenidonePlacebo
Participants with at least one dose modification5134
Participants with at least one dose interruption4012
SecondaryNumber of Participants With Dose Reductions and Treatment Interruptions During the 12-month Safety Follow-up

Number of participants with dose reduction and treatment interruptions are reported.

Time frame:
From the Follow-up Visit at Week 28 through the follow-up period of 12 Months
Reported as:
Number · Number of Participants
Number of Participants With Dose Reductions and Treatment Interruptions During the 12-month Safety Follow-up
Number of ParticipantsOpen-Label Treatment (Pirfenidone)Open-Label Treatment (Placebo)
Participants with at least one dose modification4160
Participants with at least one dose interruption2434
SecondaryNumber of Participants Withdrawn From Trial Treatment or Trial Discontinuations During the Double-Blind Period

Number of participants withdrawn from trial treatment or trial discontinuations are reported.

Time frame:
Baseline (Day 1) to Week 24
Reported as:
Number · Number of Participants
Number of Participants Withdrawn From Trial Treatment or Trial Discontinuations During the Double-Blind Period
Number of ParticipantsPirfenidonePlacebo
Number of Participants Withdrawn From Trial Treatment or Trial Discontinuations During the Double-Blind Period2512
SecondaryNumber of Participants Withdrawn From Trial Treatment or Trial Discontinuations During the 12-month Safety Follow-up

Number of participants withdrawn from trial treatment or trial discontinuations are reported.

Time frame:
From the Follow-up Visit at Week 28 through the follow-up period of 12 Months
Reported as:
Number · Number of Participants
Number of Participants Withdrawn From Trial Treatment or Trial Discontinuations During the 12-month Safety Follow-up
Number of ParticipantsOpen-Label Treatment (Pirfenidone)Open-Label Treatment (Placebo)
Number of Participants Withdrawn From Trial Treatment or Trial Discontinuations During the 12-month Safety Follow-up1926

Adverse events

Collected over Baseline (Day 1) to Week 28 in the double-blind period From the Follow-up Visit at Week 28 through the follow-up period of 12 Months in the open-label treatment period. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pirfenidone4/127 (3.1%)18/127 (14.2%)107/127 (84.3%)
Placebo7/124 (5.6%)20/124 (16.1%)81/124 (65.3%)
Open-Label Treatment (Pirfenidone)7/94 (7.4%)26/94 (27.7%)64/94 (68.1%)
Open-Label Treatment (Placebo)9/110 (8.2%)27/110 (24.5%)86/110 (78.2%)
Most frequent serious events
Showing 10 of 71
Most frequent serious events
EventPirfenidonePlaceboOpen-Label Treatment (Pirfenidone)Open-Label Treatment (Placebo)
PneumoniaInfections and infestations1/1273/1242/946/110
Interstitial lung diseaseRespiratory, thoracic and mediastinal disorders2/1274/1245/943/110
Lower respiratory tract infectionInfections and infestations1/1271/1241/944/110
Atrial fibrillationCardiac disorders0/1271/1243/940/110
DyspnoeaRespiratory, thoracic and mediastinal disorders1/1272/1242/943/110
Cardiac failure congestiveCardiac disorders1/1270/1242/941/110
Respiratory tract infectionInfections and infestations1/1270/1242/940/110
Pulmonary embolismRespiratory, thoracic and mediastinal disorders1/1270/1242/940/110
Pleuritic painRespiratory, thoracic and mediastinal disorders0/1270/1242/941/110
Pulmonary oedemaRespiratory, thoracic and mediastinal disorders0/1270/1242/940/110
Most frequent other events
Showing 10 of 26
Most frequent other events
EventPirfenidonePlaceboOpen-Label Treatment (Pirfenidone)Open-Label Treatment (Placebo)
NauseaGastrointestinal disorders40/1279/12415/9430/110
DiarrhoeaGastrointestinal disorders23/12723/1249/9415/110
DyspnoeaRespiratory, thoracic and mediastinal disorders14/12722/1249/948/110
FatigueGeneral disorders21/12719/1245/9412/110
VomitingGastrointestinal disorders14/1276/1244/9418/110
CoughRespiratory, thoracic and mediastinal disorders19/12716/12410/949/110
RashSkin and subcutaneous tissue disorders9/1277/1248/9416/110
Decreased appetiteMetabolism and nutrition disorders18/12711/1247/9413/110
DyspepsiaGastrointestinal disorders17/1277/1245/948/110
Lower respiratory tract infectionInfections and infestations8/12713/1249/9414/110

Baseline characteristics

Age, Continuous
Age, Continuous(Years)PirfenidonePlaceboTotal
Mean68.0 ± 10.167.7 ± 9.267.8 ± 9.6
Sex: Female, Male
Sex: Female, Male(Participants)PirfenidonePlaceboTotal
Female5757114
Male7069139
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PirfenidonePlaceboTotal
Hispanic or Latino7916
Not Hispanic or Latino115112227
Not reported5510
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PirfenidonePlaceboTotal
American Indian or Alaskan Native101
Asian505
Black or African American123
Other011
White120123243
08

Study locations

66 sites
  • Royal Prince Alfred Hospital
    Camperdown, New South Wales 2050, Australia
  • John Hunter Hospital; Respiratory Department; Respiratory Department
    New Lambton Heights, New South Wales 2305, Australia
  • Lung Research Queensland
    Nundah, Queensland 4101, Australia
  • Princess Alexandra Hospital, Department of Respiratory and Sleep Medicine
    Woolloongabba, Queensland 4102, Australia
  • Royal Adelaide Hospital; Respiratory Clinical Trials Unit, Thoracic Medicine
    Adelaide, South Australia 5000, Australia
  • Respiratory Department
    Heidelberg, Victoria 3084, Australia
  • The Alfred Hospital
    Prahan, Victoria 3181, Australia
  • Fiona Stanley Hospital; Advanced Lung Disease Unit
    Murdoch, Western Australia 6150, Australia
  • ULB Hôpital Erasme
    Brussels, 1070, Belgium
  • Cliniques Universitaires St-Luc
    Bruxelles, 1200, Belgium
  • UZ Leuven Gasthuisberg
    Leuven, 3000, Belgium
  • Pacifica Lung Research Center/St. Paul's Hospital
    Vancouver, British Columbia V6Z 1Y6, Canada
  • St. Joseph's Healthcare Hamilton
    Hamilton, Ontario L8N4A6, Canada
  • Fakultni Nemocnice Brno-Bohunice; Klinika Tuberkulozy A Respiracnich Chorob
    Brno, 639 00, Czechia
  • Nemocnice Jihlava
    Jihlava, 58633, Czechia
  • Fakultni nemocnice Olomouc; Pneumologicka klinika
    Olomouc, 775 20, Czechia
  • Vseobecna fakultni nemocnice v Praze; I. klinika tuberkulozy a respiracnich nemoci
    Praha 2, 128 08, Czechia
  • Aarhus Universitetshospital; Lungesygdomme, Forskning
    Aarhus N, 8200, Denmark
  • Gentofte Hospital, Lungemedicinsk Afdeling
    Hellerup, 2900, Denmark
  • Odense Universitetshospital, Lungemedicinsk Afdeling J
    Odense C, 5000, Denmark
  • Zentralklinik Bad Berka GmbH; Pneumologie
    Bad Berka, 99437, Germany
  • Evang. Lungenklinik Berlin Klinik für Pneumologie
    Berlin, 13125, Germany
  • Klinik der Justus-Liebig-Universität; Innere Medizin
    Gießen, 35392, Germany
  • Thoraxklinik Heidelberg gGmbH
    Heidelberg, 69126, Germany
  • Klinikum der Universität München; Campus Großhadern; Med. Klinik und Poliklinik V
    München, 81377, Germany
  • Sotiria Hospital for Diseases of the Chest, Academic Department of Pneumonology
    Athens, 115 27, Greece
  • University General Hospital of Athens "Attikon", B' University Pulmonary Clinic
    Chaidari, 124 62, Greece
  • University General Hospital of Heraklio, Pulmonary Clinic
    Heraklio, 711 10, Greece
  • Mater Misericordiae University hospital
    Dublin, 7, Ireland
  • St Vincents University Hospital
    Dublin, Ireland
  • Soroka; Pulmonary Clinic
    Beer Sheba, 8410101, Israel
  • Carmel Medical Center; Pulmonary Institute
    Haifa, 3436212, Israel
  • Shaare Zedek Medical Center; Pulmonary Inst.
    Jerusalem, 9103102, Israel
  • Hadassah Medical Center; Pulmonary Institute
    Jerusalem, 9112001, Israel
  • Meir Medical Center; Pulmonary Dept
    Kfar Saba, 4428164, Israel
  • Beilinson Medical Center; Pulmonary Inst.
    Petach Tikva, 4941492, Israel
  • Kaplan Medical Center
    Rehovot, 7610001, Israel
  • Ospedale Morgagni-Pierantoni; U.O. Pneumologia
    Forlì, Emilia-Romagna 47121, Italy
  • Ospedale San Giuseppe; U.O. di Pneumologia
    Milano, Lombardia 20123, Italy
  • A.O.U. Ospedali Riuniti Umberto I -G.M. Lancisi-G. Salesi Ancona; SOD Pneumologia
    Torrette Di Ancona, Marche 60100, Italy
  • A.O. Universitaria San Luigi Gonzaga di Orbassano; Ambulatorio per le Malattie Rare del Polmone
    Orbassano (TO), Piemonte 10043, Italy
  • Azienda Ospedaliero-Universitaria Careggi; SOD Pneumologia e Fisiopatologia Toracico Polmonare
    Firenze, Toscana 50134, Italy
  • Uniwersyteckie Centrum Kliniczne;Klinika Alergologii i Pneumonologii
    Gdańsk, 80-214, Poland
  • Uniwersytecki Szpital Kliniczny Nr 1 im.N.Barlickiego Oddzial Kliniczny Pneumonologii i Alergologii
    Lodz, 90-153, Poland
  • Instytut Gruźlicy i Chorób Płuc, I Klinika Chorób Płuc
    Warszawa, 01-138, Poland
  • Hospital Infante D. Pedro; Servico de Pneumologia
    Aveiro, 3814-501, Portugal
  • HUC; Servico de Pneumologia A
    Coimbra, 3000-075, Portugal
  • Hospital de Sao Joao; Servico de Pneumologia
    Porto, 4200, Portugal
  • CHVNG/E_Unidade 1; Servico de Pneumologia
    Vila Nova De Gaia, 4434-502, Portugal
  • Hospital Universitari de Bellvitge ; Servicio de Neumologia
    Hospitalet de Llobregat, Barcelona 08097, Spain
  • Hospital Universitario Marques de Valdecilla; Servicio de neumologia
    Santander, Cantabria 39008, Spain
  • Hospital Universitario La Princesa; Servicio de Neumologia
    Madrid, 28006, Spain
  • Hospital Clínico San Carlos - Servicio de Neumologia
    Madrid, 28040, Spain
  • Hospital Universitario 12 de Octubre; Servicio de Neumologia
    Madrid, 28041, Spain
  • University Hospital Birmingham Queen Elizabeth Hospital
    Birmingham, B17 0NH, United Kingdom
  • Southmead Hospital; Respiratory Department
    Bristol, BS10-5NB, United Kingdom
  • Papworth Hospital NHS Foundation Trust; Respiratory Department
    Cambridge, CB23 3RE, United Kingdom
  • Edinburgh Royal Infirmary; Respiratory Department
    Edinburgh, EH16 4SA, United Kingdom
  • Royal Devon and Exeter Hospital (Wonford)
    Exeter, EX2 5DW, United Kingdom
  • Glenfield Hospital
    Leicester, LE3 9QP, United Kingdom
  • University College London Hospital; Respiratory Medicine
    London, NW1 2BU, United Kingdom
  • Royal Brompton Hospital; Respiratory Department
    London, SW3 6NP, United Kingdom
  • Wythenshawe Hospital; North West Lung Research Centre
    Manchester, M23 9LT, United Kingdom
  • Northern General Hospital
    Sheffield, S5 7AU, United Kingdom
  • Southampton University Hospitals NHS Trust
    Southampton, SO16 6YD, United Kingdom
  • Royal Stoke University Hospital
    Stoke on Trent, ST4 6QG, United Kingdom
09

References and documents

Publications

  • Molina-Molina M, Kreuter M, Cottin V, Corte TJ, Gilberg F, Kirchgaessler KU, Axmann J, Maher TM. Efficacy of Pirfenidone vs. Placebo in Unclassifiable Interstitial Lung Disease, by Surgical Lung Biopsy Status: Data From a post-hoc Analysis. Front Med (Lausanne). 2022 Jun 17;9:897102. doi: 10.3389/fmed.2022.897102. eCollection 2022. PubMed 35783648 ↗
  • Kreuter M, Maher TM, Corte TJ, Molina-Molina M, Axmann J, Gilberg F, Kirchgaessler KU, Cottin V. Pirfenidone in Unclassifiable Interstitial Lung Disease: A Subgroup Analysis by Concomitant Mycophenolate Mofetil and/or Previous Corticosteroid Use. Adv Ther. 2022 Feb;39(2):1081-1095. doi: 10.1007/s12325-021-02009-w. Epub 2021 Dec 22. PubMed 34936057 ↗
  • Maher TM, Corte TJ, Fischer A, Kreuter M, Lederer DJ, Molina-Molina M, Axmann J, Kirchgaessler KU, Samara K, Gilberg F, Cottin V. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respir Med. 2020 Feb;8(2):147-157. doi: 10.1016/S2213-2600(19)30341-8. Epub 2019 Sep 29. PubMed 31578169 ↗
  • Graney BA, Fischer A. Interstitial Pneumonia with Autoimmune Features. Ann Am Thorac Soc. 2019 May;16(5):525-533. doi: 10.1513/AnnalsATS.201808-565CME. PubMed 30695649 ↗
  • Maher TM, Corte TJ, Fischer A, Kreuter M, Lederer DJ, Molina-Molina M, Axmann J, Kirchgaessler KU, Cottin V. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: design of a double-blind, randomised, placebo-controlled phase II trial. BMJ Open Respir Res. 2018 Sep 4;5(1):e000289. doi: 10.1136/bmjresp-2018-000289. eCollection 2018. PubMed 30233802 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2017 to primary completion in Nov 2018, 18 months.

Results were first posted in Jan 2020, 1 year 1 month after primary completion.

Of 53 phase 2 interventional studies under Lung Diseases, Interstitial, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 71. This study's 18 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 31, 2017
First posted
Apr 4, 2017
StartActual
May 15, 2017
Primary completionActual
Nov 21, 2018
CompletionActual
Jan 10, 2020
Results first posted
Jan 3, 2020
Last update
Jan 13, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 13, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03099187
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Apr 4, 2017
Start date
May 15, 2017
Primary completion
Nov 21, 2018
Completion
Jan 10, 2020
Results posted
Jan 3, 2020
Last update
Jan 13, 2021

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pirfenidone

Start the discussion